Title

Diagnosing pediatric mitochondrial disease: lessons from 2,000 exomes

Authors

Sarah L. Stenton^{1,2}, Masaru Shimura^{1,2}, Dorota Piekutowska-Abramczuk³, Peter Freisinger⁴, Felix Distelmaier⁵, Johannes A. Mayr⁶, Christine Makowski⁷, Boriana Büchner⁸, Bader Alhaddad^{1,2}, Charlotte L. Alston^{9,10}, Anna Ardissone¹¹, Rui Ban^{1,2,12}, Ivo Barić¹³, Riccardo Berutti^{1,2}, Theresa Brunet¹, Elżbieta Ciara³, Dasha Deen⁹, Julien Gagneur¹⁴, Daniele Ghezzi^{11,15}, Mirjana Gusic^{1,2}, Tobias B. Haack^{1,16}, Maja Hempel¹⁷, Ralf A. Husain¹⁸, Daniela Karall¹⁹, Stefan Kölker²⁰, Urania Kotzaeridou²⁰, Thomas Klopstock⁸, Robert Kopajtich^{1,2}, Vassiliki Konstantopoulou²¹, Steffen Liez²², Dominic Lenz²⁰, Albert Z. Lim⁹, Hanna Mandel²³, Robert McFarland⁹, Wolfgang Müller-Felber²⁴, Gerard Muñoz-Pujol²⁵, Akira Ohtake²⁶, Yasushi Okazaki²⁷, Rikke Olsen²⁸, Ewa Pronicka³, Angela Pyle⁹, Antonia Ribes²⁵, Dariusz Rokicki³, René Santer¹⁷, Manuel Schiff^{29,30}, Markus Schuelke³¹, Dmitrii Smirnov^{1,2}, Wolfgang Sperl⁶, Tim Strom¹, Frederic Tort²⁵, Polina Tsygankova³², Rudy van Coster³³, Patrick Verloo³³, Jürgen-Christoph von Kleist-Retzow³⁴, Ekkehard Wilichowski³⁵, Tekla Wolstein^{1,2}, Manting Xu¹², Vicente Yépez^{1,14}, Michael Zech^{1,2}, Saskia Wortmann^{6,36}, Matias Wagner^{1,2}, Costanza Lamperti¹¹, Robert W. Taylor^{9,10}, Fang Fang¹², Agnés Rötig³⁰, Kei Murayama³⁷, Thomas Meitinger¹, Holger Prokisch^{1,2}

Affiliations

- 1. Institute of Human Genetics, Technical University of Munich, Germany.
- 2. Institute of Neurogenomics, Helmholtz Zentrum München, Germany.
- 3. The Children's Memorial Health Institute, Warsaw, Poland.
- 4. Klinikum Reutlingen, Reutlingen, Germany.
- 5. Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
- 6. University Children's Hospital, Paracelsus Medical University, Salzburg, Austria.
- 7. Department for Paediatric and Adolescent Medicine, Schwabing Hospital, Munich, Germany.
- 8. Ludwig Maximilian University of Munich, Munich, Germany.
- Wellcome Centre for Mitochondrial Research, Translational and Clinical Research
 Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne,
 UK.
- 10. NHS Highly Specialised Services for Rare Mitochondrial Disorders, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Queen Victoria Road, Newcastle upon Tyne, UK.
- Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
- 12. Beijing Children's Hospital, Beijing, China.
- 13. School of Medicine Zagreb, Zagreb, Croatia.
- 14. Department of Informatics, Technical University of Munich, Garching, Germany.
- 15. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
- 16. Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

- 17. Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- 18. Centre for Inborn Metabolic Disorders, Department of Neuropediatrics, Jena University Hospital, Jena, Germany.
- Medizinische Universität Innsbruck Department für Kinder- und Jugendheilkunde, Innsbruck, Austria.
- 20. Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany.
- 21. Medical University of Vienna, Vienna, Austria.
- 22. Klinikum Dritter Orden, Munich, Germany.
- 23. Rambam Medical Center in Haifa, Haifa, Israel.
- 24. Dr. von Hauner Children's Hospital, LMU Munich, Munich, Germany.
- 25. Section of Inborn Errors of Metabolism-IBC. Department of Biochemistry and Molecular Genetics. Hospital Clinic de Barcelona, IDIBAPS, CIBERER, Barcelona, Spain.
- 26. Department of Pediatrics, Saitama Medical University, Saitama, Japan.
- 27. Juntendo University Graduate School of Medicine, Tokyo, Japan.
- 28. Research Unit for Molecular Medicine, Department for Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
- 29. Necker Hospital, APHP, Reference Center for Inborn Error of Metabolism, Pediatrics Department, University of Paris, Paris, France.
- 30. Inserm UMR S1163, Institut Imagine, Paris, France.
- 31. Charité Universitätsmedizin Berlin, Department of Neuropediatrics, Berlin, Germany.
- 32. Department of Inherited Metabolic Diseases, Moscow, Russia.
- 33. Ghent University Hospital, Ghent, Belgium.

34. University of Cologne, Faculty of Medicine and University Hospital Cologne,

Department of Pediatrics, Cologne, Germany.

35. Universitätsmedizin Göttingen, Göttingen, Germany.

36. Radboud Centre for Mitochondrial Medicine, Amalia Children's Hospital,

Radboudumc, Nijmegen, The Netherlands.

37. Chiba Children's Hospital, Chiba, Japan.

Abstract

Background: The spectrum of mitochondrial disease is genetically and phenotypically

diverse, resulting from pathogenic variants in over 400 genes, with aerobic energy

metabolism defects as a common denominator. Such heterogeneity poses a significant

challenge in making an accurate diagnosis, critical for precision medicine.

Methods: In an international collaboration initiated by the European Network for

Mitochondrial Diseases (GENOMIT) we recruited 2,023 pediatric patients at 11

specialist referral centers between October 2010 and January 2021, accumulating

exome sequencing and HPO-encoded phenotype data. An exome-wide search for

variants in known and potential novel disease genes, complemented by functional

studies, followed ACMG guidelines.

Results: 1,109 cases (55%) received a molecular diagnosis, of which one fifth have

potential disease-modifying treatments (236/1,109, 21%). Functional studies enabled

diagnostic uplift from 36% to 55% and discovery of 62 novel disease genes. Pathogenic

variants were identified within genes encoding mitochondrial proteins or RNAs in 801

cases (72%), while, given extensive phenotype overlap, the remainder involved proteins targeted to other cellular compartments. To delineate genotype-phenotype associations, our data was complemented with registry and literature data to develop "GENOMITexplorer", an open access resource detailing patient- (n=3,940), gene-(n=427), and variant-level (n=1,492) associations (prokischlab.github.io/GENOMITexplorer/).

Conclusions: Reaching a molecular diagnosis was essential for implementation of precision medicine and clinical trial eligibility, underlining the need for genome-wide screening given inability to accurately define mitochondrial diseases clinically. Key to diagnostic success were functional studies, encouraging early acquisition of patient-derived tissues and routine integration of high-throughput functional data to improve patient care by uplifting diagnostic rate.

Introduction

Mitochondrial disease (MD) is an umbrella term for a group of complex metabolic disorders predominantly affecting mitochondrial oxidative phosphorylation (OXPHOS) (Gorman et al., 2016). To date, pathogenic variants in over 400 genes have been identified in both mitochondrial (mtDNA) and nuclear DNA, accounting for approximately 10% (416/4,022) of disease-associated genes in the Online Mendelian Inheritance in Man (OMIM) database (https://omim.org). MD has a minimum prevalence rate of 1 per 5,000 (Gorman et al., 2015). The absence of reliable biomarkers has led to MDs largely being defined by clinical criteria, some of which have been formalized into scoring systems (Morava et al., 2006, Witters et al., 2018). However,

due to marked phenotypic overlap with non-MDs (Wortmann et al., 2015), here termed "MD-phenocopies", limited phenotypic congruence, even between MD patients of shared molecular cause, and conversely, vast genetic heterogeneity amongst MD patients with a similar phenotype, MDs are most accurately defined on the molecular genetic level.

In recent years, genome-wide approaches including whole exome sequencing (WES) (Taylor et al., 2014, Ohtake et al., 2014, Wortmann et al., 2015, Legati et al., 2016, Kohda et al., 2016, Pronicka et al., 2016, Puusepp et al., 2018, Theunissen et al., 2018) and whole genome sequencing (WGS) (Riley et al., 2020) have been utilized in the diagnostic setting for MD. These approaches have overcome the need to prioritize candidate genes for targeted analysis in MD, such as by an invasive tissue biopsy followed by measurement of mitochondrial respiratory chain complex (RCC) activities (Wortmann et al., 2017). Current studies analyzing up to 142 patients from single centers report a wide range of WES/WGS diagnostic yields in suspected cases of MD (35-62%) depending on the age of onset, clinical evidence of MD, and the confirmation of a mitochondrial RCC defect (reviewed in Stenton and Prokisch 2020).

Here, analyzing over 2,000 patients by WES in an international multi-center collaborative effort, we uncover the genetic landscape of suspected MD, demonstrating high impact on clinical practice by identifying diagnoses with defect-specific therapy benefiting from early intervention and outlining a trajectory for the routine integration of high-throughput functional data to improve patient care by uplifting diagnostic rate.

Methods

Study population

We performed an analysis of 2,023 pediatric-onset (<18 years) patients analyzed by WES by one of 11 diagnostic referral centers specializing in MD in Europe and Asia between October 2010 and January 2021 (**Table S1**). Patients were eligible for inclusion if: (i) no genetic diagnosis was made by targeted sequencing (including complete mtDNA sequencing in some centers) or no prior genetic testing had been performed, and (ii) the patient had at least a "possible" MD according to the Nijmegen Mitochondrial Disease Criteria (MDC) (Morava et al., 2006). 293/2,023 patients (14%) were previously reported as part of focused research studies or novel disease gene descriptions (49 MD genes, 13 MD-phenocopy genes, **Table S2**). All participants or their legal guardians completed written informed consent and the study was approved by local ethical committees of the participating centers. A summary of the analysis workflow and study resources is depicted in **Fig. 1**.

Genetic analyses

Experimental procedures were performed in the respective centers, as detailed in the **Supplemental Methods**. All disease-causing variants were classified according to the ACMG criteria (Richards et al., 2015) (**Table S3**) and were submitted to the ClinVar database or are in progress.

Mitochondrial disease gene definition

MD genes were defined as per Schlieben and Prokisch 2020 (n=413), with the addition of three recently identified MD genes (*DNAJC30*, *LIG3*, and *MRPL38*) (Stenton et al.,

2021, Kopajtich et al., 2021, Bonora et al., 2021). This definition included 49 of 62 novel gene discoveries made in this cohort (**Table S2**).

Phenotype analyses

Patient phenotype data were extracted as human phenotype ontology (HPO) terms (Köhler et al., 2021) from medical records and/or patient registries. All ancestral HPO terms were derived from the ontology using the R package "OntologyX" (Greene et al., 2017). MDC scoring was standardized for the usage of HPO terms (**Supplemental Methods**). Symmetric semantic similarity (SS) was calculated between patient HPO terms and established disease-gene associated HPO terms using the R package "PCAN" and the HPO "genes to phenotype" annotation files (human-phenotype-ontology.github.io/downloads.html, accessed April 2021), limited to disease genes in the OMIM database (https://www.omim.org, accessed April 2021) (n=4,022).

Statistical analyses

Statistical analyses were performed in R version 3.6.1. Enrichment analyses used the Fisher's exact test. Bonferroni correction was used to adjust p values for multiple testing. A significance level of 0.05 was used. Correlation was tested using Spearman's rank method. Diagnostic test performance was analyzed by ROC (receiver operating characteristic) curves and calculation of the AUC (area under the ROC curve) with 95% confidence intervals (CI).

Results

Study population description

2,023 pediatric patients (1,950 index patients plus 73 affected siblings) were analyzed by singleton (1,779/2,023, 88%) or trio (244/2,023, 12%) WES. 1,066/2,023 patients were male (53%). The age of onset ranged from neonatal to juvenile, with over one third of patients presenting in infancy (709/2,023, 35%) (**Table 1**).

In total, 949 unique non-redundant HPO terms were extracted, a median of eight HPO terms per patient (range 2-40) across a median of four organ systems (range 1-12) (**Table 1**, **Supplemental Fig. 1a-b**). 321/2,023 patients (16%) presented with a constellation of symptoms indicative of Leigh syndrome (**Table S4**, Rahman et al., 1996) and only 37/2,023 patients (2%) with symptoms suggestive of MELAS syndrome (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes, n=20), Alpers syndrome (n=10), Kearns-Sayre syndrome (n=2), MERRF (Myoclonic Epilepsy with Ragged Red Fibers, n=1), NARP (Neuropathy, Ataxia, and Retinitis Pigmentosa, n=1), and LHON (Leber Hereditary Optic Neuropathy, n=3). The remaining 1,665/2,023 patients (82%) did not present with a distinct MD syndrome.

Diagnostic rate

A molecular diagnosis was made by WES in 1,109/2,023 patients (55%) (**Fig. 1** and **Fig. 2a**). A dual diagnosis was identified in 7 patients (0.3%). In 263/2,023 patients (13%), the WES analysis remained unsolved with variants of uncertain significance

(VUS) identified in OMIM disease genes or candidate disease genes. In the remaining 651/2,023 patients (32%) no variant could be prioritized for further consideration. By comparison, applying a filter restricting the observed disease-causing variation to genes covered by 13 "mitochondrial disease" panels (see **Supplemental Methods**) resulted in a diagnostic rate of 27% (± 7% s.d.) (**Supplemental Fig. 2a**).

Molecular genetic etiologies

The disease-causing variants were detected in 199 different MD genes (150 known and 49 novel) in 801/1,109 (72%) solved cases (**Fig. 2a-b**). In the remaining 308/1,109 solved cases (28%), the molecular diagnosis involved a MD-phenocopy gene (181 known and 13 novel disease genes) primarily implicated in neurodevelopmental disease, neuromuscular disease, or other inborn errors of metabolism (**Supplemental Fig. 2b**).

The molecular diagnoses spanned 393 genes, many of which were reported in single cases only (208/393, 53%). The most frequent MD gene hits were *PDHA1*, *ECHS1*, *MT-ATP6*, and *ACAD9* each with ≥23 cases (**Fig. 2c**). Amongst the MD gene hits were 29 defects identified in 177 patients where defect-specific vitamin supplementation, replenishment of a critical cofactor, dietary modification, or idebenone therapy offers the potential for targeted disease-modifying treatment (**Fig. 2d**) (**Table S5**) (Bick et al., 2020, Hoytema van Konijnenburg et al., 2021, Distelmaier et al., 2017). The most frequent MD-phenocopy gene hits were *MORC2*, *MECP2*, and *POLR3A*, each with ≥6 cases.

Pathogenic mtDNA variants accounted for 15% (118/801) of MD molecular diagnoses and were mostly heteroplasmic (71/118 cases, 60%). In the remaining majority (683/801, 85%) the causative gene defect was nuclear-encoded and inherited in an autosomal recessive manner (606/683 cases, 89%) (**Fig. 2e**), of which 306/606 harbored a homozygous causative variant (51%). When searching for runs of homozygosity, a first- or second-degree parental relationship was suspected in a total of 44/2,023 cases, accounting for 35/306 cases with homozygous "pathogenic" or "likely pathogenic" variants in MD genes (11%). In contrast to MD, *de novo* dominant variants were responsible for disease in significantly more MD-phenocopy cases (4% of MD and 20% of MD-phenocopy, p-value 1.5×10⁻¹⁵, Fisher's exact test) (**Table 1**). However, *de novo* variants were also frequently detected in mtDNA-encoded MD genes (7 cases) and in the nuclear-encoded MD gene *PDHA1* (14 cases, four by trio analysis and 10 by detection of the heterozygous variant in singleton analysis followed by parental sequencing).

In total, 1,492 disease-causing variants were reported (1,173 unique variants) (**Table S3, Supplemental Fig. 2c-e**). 406/1,492 variants (27%) were already documented as "pathogenic" or "likely pathogenic" in ClinVar or MITOMAP at the time the patient's molecular diagnosis was made (**Fig. 2f**). Missense variants accounted for the largest proportion of all disease-causing variants (817/1,492 variants, 55%), of which the majority (550/649 unique missense variants, 85%) were reported in single cases only. In 304/538 cases carrying a missense variant (57%), the variant was homozygous or compound heterozygous with a second missense variant, posing a challenge to interpretation of pathogenicity and requiring functional studies to provide evidence of pathogenicity (**Fig. 1** and **Fig. 2g**). In contrast, biallelic null variants were identified in

just 162/1,109 solved cases (15%). Notably, in 33/1,109 solved cases, pathogenic CNVs were identified, of which in three cases, the CNV was in *trans* with a single nucleotide variant.

Genotype-phenotype associations

Most patients came to medical attention with neurological (1,568/2,023, 78%), metabolic (1,541/2,023, 76%), muscular (1,066/2,023, 53%), digestive (579/2,023, 29%), and/or cardiological (574/2,023, 28%) symptoms (Fig. 3a and Supplemental Fig. 3a). In solved MD patients, the most frequently reported clinical and imaging findings were neurodevelopmental abnormality (546/801, 68%) and abnormality of basal ganglia and/or brainstem MRI signal intensity (404/801, 50%). The most prevalent laboratory findings were increased serum lactate (506/801, 63%) and abnormal activity of mitochondrial RCC enzymes (389/801, 49%) (Fig. 3a). Across the entire cohort, 83 HPO terms were reported in ≥50/2,023 patients. None of these HPO terms were entirely specific for MD. However, 9/83 HPO terms were significantly enriched in the solved MD patients in comparison to the MD-phenocopies, including HPO terms indicative of Leigh-like syndrome (encephalopathy, abnormality of the basal ganglia and/or brainstem, and increased serum lactate), mitochondrial RCCI defect, and cardiomyopathy (Fig. 3a, Table S6). In combination, HPO terms indicative of Leigh syndrome (Table S4) were highly suggestive of MD (OR 3.25, 95% CI 2.0-5.5, p 1.1×10^{-7} , Fisher's exact test).

To objectively categorize patients by the level of clinical evidence of MD, we applied the Nijmegen MDC score (Morava et al., 2006), demonstrating a continuum from "possible" (590/2,023, 29%, score 2-4) to "probable" (804/2,023, 40%, score 5-7) and "definite" (629/2,023, 31%, score 8-12) MD (**Fig. 3b**). Increase in the Nijmegen MDC score was reflected by increase in the overall diagnostic rate, increase in the proportion of molecularly diagnosed MD, and decrease in the proportion of MD-phenocopies. Notably, a "definite" MD (score 8-12) was reported in 55/308 MD-phenocopy patients. Given these data, no clear threshold of Nijmegen MDC score for the accurate diagnosis of an MD can be drawn in our cohort (**Fig. 3b**) and the ability of both Nijmegen and Revised MDC (Witters et al., 2018) scoring and elevated serum lactate was found to be limited in discerning between MD and MD-phenocopy (**Fig. 3c**, **Table S7**).

In 188/914 (21%) unsolved cases, VUS were detected in known disease genes in keeping with the expected mode of inheritance. In a subset (143/188, 76%), the VUS occurred in one of 72 MD genes or 43 candidate disease genes with strong evidence of mitochondrial localization (according to Mitocarta3.0). In comparison to the remaining unsolved cases, these 143 cases had significantly more reports of elevated serum lactate, mitochondrial RCC defect(s), and a phenotype combination indicative of Leigh syndrome (Fig. 3d, Table S8), clinical features providing supportive evidence for the pathogenicity of the variant(s). However, current unavailability of fibroblast cell lines hindered further functional studies to confirm pathogenicity, highlighting the importance of acquiring these bio-samples early in the diagnostic process.

Akin to MDC scoring, the ability of HPO semantic similarity (SS) scoring to retrospectively predict the patient's molecular diagnosis was limited. The correct molecular diagnosis had the highest SS score amongst all OMIM disease genes in just 3% of cases, increasing to 6% and 9% when considering the three and five highest SS

scores, respectively (**Fig. 3e**). Overall, more complex phenotypes correlated with improved SS scoring (R 0.39, p 2.2x10⁻¹⁶, Spearman's rank correlation) (**Supplemental Fig. 3b**).

GENOMITexplorer

The open access online resource "GENOMITexplorer" lists all "pathogenic" and "likely pathogenic" variants reported in this study with the respective predicted function, heteroplasmy level, allele frequency (according to gnomAD), CADD score, SIFT score, ACMG classification, functional evidence, and phenotype SS score. HPOgene associations for all patients included in the study (n=2,023) in addition to pediatric molecularly diagnosed patients from mitochondrial disease registries (mitoNET and Besta, n=318) and from literature reports (n=1,599) are provided on the patient-(n=3,940, 3,026 molecularly diagnosed), gene- (n=427), and variant level (available for n=1,492). The most discriminating phenotypes by genetic diagnosis can be explored for all genes with \geq 5 (n=114) reported patients carrying "pathogenic" and "likely pathogenic" variants.

Discussion

We analyzed over 2,000 pediatric patients by WES under the clinical suspicion of MD. This is the largest study of its kind and was made possible only by broad international collaboration. A molecular diagnosis was made in just over 50% of cases and 62 novel disease genes discoveries were made in the cohort over a 10-year period (49 MD, 13 MD-phenocopy), illuminating underlying disease mechanism for the application or

development of specific treatments not considered previously. This high diagnostic rate was achieved by close interconnection between research and routine diagnostics, and places suspected MD amongst the highest yielding metabolic and neurological primary indications for WES (on average 20-35%) (Supplemental Fig. 4a).

By nature, the study focused on more difficult cases referred to specialist centers. Therefore, despite providing a reliable estimate of the power of WES in MD given the size of the study, it does not intend to provide an epidemiological perspective. The diagnostic rate is conservative, as across our centers we diagnose at least 15% of patients without WES, mostly by mtDNA sequencing (see **Fig. 1**). Further, we do not see the patients diagnosed prior to referral to a specialist center. Therefore, had WES been applied as a first step in the diagnostic pathway in all patients, the yield would have been considerably higher. This is reflected by the most recent 250 patients analyzed in Munich, Germany, where WES is the first genetic test in the majority and the diagnostic rate was >60%. Moreover, in a further 7% (143/2,023) of patients in the study, we identified VUS in established or candidate MD genes with clear clinical evidence of MD and thereby high likelihood for pathogenic designation upon future functional studies.

Functional studies of patient-derived material provided significant value for variant interpretation, necessitated by the preponderance of private missense variants with no prior functional annotation (>80%). Without functional validation, our diagnostic rate would have been capped at approximately 35% (see **Fig. 1**), strongly arguing for proactive bio-sampling of patients, (e.g., a minimally invasive skin biopsy to establish a fibroblast cell line), and parallel analysis of WES and functional data. Fibroblasts are

an excellent resource for the study of many MDs, as they may be used for mitochondrial RCC measurement with results comparable to invasive muscle biopsy (Ogawa et al., 2017, Wortmann et al., 2017) and detection of impaired mitochondrial respiration by measurement of oxygen consumption rate or other biomarkers. Moreover, fibroblasts open the option for multi-omic studies, pioneered in MD, such as RNA sequencing and proteomics (Kremer et al., 2017, Kopajtich et al., 2021, Yepez et al., 2021). These multi-omics assays pave the way for integrated high throughput functional readouts of variant consequence, allowing interpretation of the vast number of VUS detected by WES/WGS.

With the continuous discovery of novel disease genes (>300 per year in OMIM and 212 MD genes during the course of this study) (**Supplemental Fig. 4b**), the expansion of genotype-phenotype associations, and the description of different modes of inheritance for established disease genes, WES reanalysis becomes an essential component of the diagnostic pathway. Reanalysis uplifted our diagnostic rate by almost 5% (see **Fig. 1**). A prime example was the diagnosis of 11 patients with pathogenic *de novo* dominant variants in *MORC2* by reanalysis following a report expanding the phenotypic spectrum to include neurodevelopmental and metabolic abnormalities (Guillen Sacoto et al., 2020).

Reaching a genetic diagnosis is important for defect-specific treatments, disease prevention, and genetic and reproductive counselling. Moreover, it is a prerequisite for inclusion in constantly ongoing clinical trials, an area in which there has been immense progress driven by increased understanding of disease pathomechanism and the unmet clinical need, reflected by over 50 registered clinical trials for MD (Russell et al., 2020).

In our cohort, disease-modifying treatments, such as a ketogenic diet in *PDHA1* defects, are reported based on case reports for 29 of the identified MD gene defects, across 177 patients in our study (Bick et al., 2020, Hoytema van Konijnenburg et al., 2021, Distelmaier et al., 2017), as exemplified in our earlier publications (Stenton et al., 2021, Zhou. L. et al., 2020, Zhou. J. et al., 2020, Repp et al., 2018, Distelmaier et al., 2013, Haack et al., 2012). In addition, 43 of the identified disease genes in the MD-phenocopies across 61 patients, have reported treatments. In total, these 238 patients (236/1,109 solved cases, 21%) endorse an unbiased exome-wide approach to identify and optimize care for unexpected diseases without delay.

Despite the clinical challenges to diagnose MD correctly, over 70% of the solved cases were confirmed as such, with defects equally distributed across all classes of mitochondrial function (Fig. 4). A preponderance of nuclear DNA variants (85%) and autosomal recessive inheritance (>75%) in the solved MD patients was anticipated for a pediatric population (Barca et al., 2020). These figures are, however, inflated by ascertainment bias given thorough mtDNA analysis undertaken earlier in the diagnostic pathway in some centers. *PDHA1*, *ECHS1*, and *ACAD9* were the most frequent nuclear-encoded MD genes with pathogenic variants, in-keeping with large collections of patients in the literature (Lissens et al., 2000, Marti-Sanchez et al., 2020, Repp et al., 2018) and the report of founder mutations in *ECHS1* (Haack et al., 2015, Tetreault et al., 2015), encouraging the implementation of clinical trials for these defects. Nevertheless, certain mtDNA-encoded genes with wide clinical variability, such as *MT-ATP6*, were frequent hits in line with large mutation reports (Ganetzky et al., 2019, Ng et al., 2019, Stendel et al., 2020). This reinforces the value of calling mtDNA variants from WES data in a blood sample from children. The low frequency of certain

nuclear-encoded molecular diagnoses in our study may be distorted by prior targeted sequencing of candidate disease genes, such as *POLG* (7 diagnoses) and *SURF1* (10 diagnoses), two of the most frequently reported nuclear-encoded MDs in the literature (Rahman and Copeland 2019, Barca et al., 2020, Tan et al., 2020). Importantly, >20% of genetic diagnoses were made in MD-phenocopy genes, only identifiable by opting for unbiased exome-wide capture of variation. Amongst the MD-phenocopies we report 6-fold more autosomal dominant and *de novo* dominant inheritance of disease, highlighting the importance of trio WES to streamline variant interpretation.

Within our study, encephalopathy, cardiomyopathy, MRI signal intensity changes in the basal ganglia and/or brainstem, elevated serum lactate, and mitochondrial RCC defects were found to be the most enriched HPO terms in molecularly diagnosed MD patients. However, given extensive phenotypic overlap with other Mendelian diseases, MDC scoring were unable to reliably stratify the MD and MD-phenocopy patients, and HPO phenotype semantic similarity scoring prioritized the correct molecular diagnosis in less than 5% of patients, a figure considerably lower than reported for general pediatric genetic studies (French et al., 2019). For these reasons, MD is most efficiently and reliably diagnosed by WES early in the diagnostic pathway to direct the need for specific clinical investigations and to prevent unnecessary interventions in children. Moreover, the clinical heterogeneity is not only within the spectrum of MD, but also between variants within a single gene defect (Marti-Sanchez et al., 2020), indicating the need to study MDs on the variant level. A starting point is GENOMITexplorer, providing patient- and variant-level resolution of genotype-phenotype associations, so far of only limited availability in the established databases (Firth et al., 2009).

We were unable to provide a molecular diagnosis for just under half of the investigated patients. The possible reasons for this are manifold: (i) due to pitfalls in variant prioritization, such as single heterozygous de novo variants, given the majority of patients underwent singleton WES analysis, and pitfalls in variant interpretation (e.g., hypomorphic and synonymous variants causing abnormal splicing, and deep intronic and regulatory variants), a limitation beginning to be addressed by multi-omic integration (Kopajtich et al., 2021); (ii) due to certain genetic variants being undetectable by WES given insufficient depth of coverage, locus-specific features (e.g., GC-rich regions and homopolymeric repeats), sequencing biases, and genomic alterations (e.g., large deletions, insertions, chromosomal rearrangements, short tandem repeats), the inability to delineate some of these alterations may be overcome by WGS, specifically long-read sequencing; (iii) due to the high number of VUS found in genes clinically compatible with the patient's phenotype, the possibility to perform functional studies is fundamental to achieve a definitive diagnosis; and (iv) due to individuals with suspected MD carrying pathogenic variants in as yet unidentified disease-relevant genes, the discovery of which continues year-on-year (Supplemental Fig. 4b). Such disease gene discoveries, as exemplified by the 62 novel disease gene discovered in this cohort, are accelerated by collation of patient datasets to increase the signal for detection. In this manner, more challenging diagnoses can be made, such as variants with incomplete penetrance as recently described for *DNAJC30*, a novel recessive MD manifesting as LHON that is responsive to idebenone therapy (Stenton et al., 2021). This underpinned our motivation to form an international MD network and encourages patient referral to centers of expertise in which research projects flank state of the art diagnostics and act as recruitment centers for clinical trials.

Overall, our study demonstrates the power and efficiency of WES and functional validation in specialized centers in diagnosing patients with suspected MD, revealing that a substantial proportion of MD patients benefit from early diagnosis and targeted treatment, and exemplifying health economic benefits from the application of WES early in the diagnostic pathway.

Online resources

GENOMITexplorer (prokischlab.github.io/GENOMITexplorer/)

GENOMIT (genomit.eu)

ClinVar (ncbi.nlm.nih.gov/clinvar/)

MITOMAP (mitomap.org)

gnomAD (gnomad.broadinstitute.org)

OMIM (omim.org)

Acknowledgements

The authors acknowledge support by the German Federal Ministry of Education and Research (BMBF, Bonn, Germany) awarded grant to the German Network for Mitochondrial Disorders (mitoNET, 01GM1906A), the German BMBF and Horizon2020 through the E-Rare project GENOMIT (01GM1920A, genomit.eu), and the ERA PerMed project PerMiM (01KU2016A, permim.eu). AR and MS acknowledge the Association Français contre les Myopathies, GIS-Institut des Maladies Rares, French Agence Nationale pour la Recherche (A.N.R.), Association contre les Maladies Mitochondriales (AMMi), Fondation Maladies Rares,

Collaboration CEA/IG/CNG-INSERM, MSD-Avenir for Devo-Decode project, and Bioresources of the Necker Imagine DNA biobank (BB-033-00065). RM and RWT are supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Lily Foundation and the UK NHS Specialised Commissioners who fund the "Rare Mitochondrial Disorders of Adults and Children" Service in Newcastle upon Tyne. CLA is supported by an NIHR postdoctoral fellowship (PDF-2018-11-ST2-02). AR, GMP, and FT were supported by the Instituto de Salud Carlos III (PI16/01048; PI19/01310) (Co-funded by European Regional Development Fund "A way to make Europe") and the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), an initiative of the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovación, Spain), the Departament de Salut, Generalitat de Catalunya (URDCAT project, SLT002/16/00174), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) (2017: SGR 1428) and the CERCA Programme/Generalitat de Catalunya. TK is a member of the European Reference Network for Rare Neurological Diseases (ERN-RND-Project ID No 739510). TBH was supported by the German Bundesministerium für Bildung und Forschung (BMBF) through the Juniorverbund in der Systemmedizin "mitOmics" (FKZ 01ZX1405). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Figure legends

Figure 1. Diagnostic workflow for patients clinically suspected of MD. Based on the experience of the mitochondrial centers in the UK and Italy, an estimated 15% of pediatric patients receive a molecular diagnosis by targeted gene sequencing prior to WES (≤5 individual genes or mtDNA sequencing), the majority of which have pathogenic variants in the mtDNA. This study analyzed 2,023 patients investigated by WES. Patients were referred to one of 11 diagnostic referral centers specialized in MD (Table S1). DNA was extracted from blood for WES and clinical data were collected from the medical records and/or patient registries for HPO extraction. Patient DNA was sequenced between October 2010 and January 2021. The WES diagnostic rate was stratified by immediate diagnoses (i.e., the identification of ACMG classified "pathogenic" or "likely pathogenic" variants in a known disease gene in-keeping with the patient's clinical presentation) (619/2,023, 31%), diagnoses in known disease genes requiring further functional studies (293/2,023, 14%), diagnoses leading to the discovery and functional validation of a novel disease gene (107/2,023, 5%, 49 novel MD genes and 13 novel MD-phenocopy genes), and diagnoses identified by reanalysis of the WES data (90/2,023, 4%, mean 2.6 year \pm 1.7 year s.d. interval required). The cases solved by reanalysis were retrospectively identified as those with "pathogenic" or "likely pathogenic" variants in disease genes only described to be disease-associated following the initial WES analysis. Of these cases, 53 molecular diagnoses were made in MD genes and 37 in MD-phenocopy genes. The resources for functional validation studies included 457 patient-derived fibroblast cell lines (23% of the cohort) and 1,103 tissue biopsy samples including skeletal muscle, cardiac muscle, and liver (55% of the cohort). HPO, human phenotype ontology; WES, whole exome sequencing.

Figure 2. Molecular etiology of the MD and MD-phenocopies. A, Number of solved and unsolved cases stratified by underlying molecular cause. B, Proportion of solved cases in known and novel disease genes (defined as novel at the point of molecular diagnosis, i.e., whether the case was involved in one of the 62 novel disease gene discoveries). C, Proportion of molecular diagnoses made in a single case and multiple cases. Those detected in ≥ 5 cases are individually displayed with their frequency. The most frequent genes with disease-causing variants in the MD-phenocopy patients are highlighted in light blue. **D**, Solved MD patients with variants in one of 29 MD genes reported to have a potential treatment option, stratified by treatment type. E. Proportion of molecular diagnoses by mode of inheritance in the MD and MD-phenocopy patients. F, Proportion of variants listed in ClinVar or MITOMAP as "pathogenic" (P) or "likely pathogenic" (LP) at the point of molecular diagnosis. G, Proportion of variants of each functional class in the MD patients, MD-phenocopy patients, and all solved cases collectively. Most variants were missense. The proportion of missense variants detected in a single case and multiple cases is depicted with the corresponding functional validation study leading to designation of the variant as "pathogenic" or "likely pathogenic". WES, whole exome sequencing; VUS, variant of uncertain significance; CNV, copy number variant.

Figure 3. Comprehensive overview of patient phenotype and association with the molecular diagnosis. A, Frequency of HPO terms reported in ≥50/2,023 patients, stratified by the underlying molecular diagnosis (left panel). HPO term enrichment analysis comparing solved MD and MD-phenocopy patients (right panel) depicting the odds ratio with the 95% confidence interval (confidence interval limits >5 are not

shown, see Table S6). Nominally significant results are depicted in color and results with multiple testing corrected significance are depicted with filled shapes (adjusted pvalue ≤0.05). B, Distribution of Nijmegen MDC score (grey bars) in the study population and the corresponding correlation to the diagnostic rate (purple), proportion of mutations in MD genes (green), and proportion of mutation in MD-phenocopy genes (blue). Increase in the Nijmegen MDC score was reflected by increase in the overall diagnostic rate (R 0.86, p 1.3×10⁻³, Spearman's rank correlation), increase in the proportion of solved MD (R 0.92, p 2.2×10⁻¹⁶, Spearman's rank correlation), and decrease in the proportion of MD-phenocopies (R -0.96, p 2.4×10⁻⁶, Spearman's rank correlation). The unexpectedly high diagnostic rate and proportion of solved MD at a Nijmegen MDC score of 2 (120 cases) reflects 114 legacy cases where only limited clinical information was available and six cases with single organ involvement (e.g., optic atrophy). C, Receiver operator characteristic (ROC) curves for the Nijmegen MDC score (AUC MD vs. MD-phenocopy 0.68, 95% CI 0.64-0.71), Revised MDC score (AUC MD vs. MD-phenocopy 0.63, 95% CI 0.60-0.67), and elevated serum lactate (AUC MD vs. MD-phenocopy 0.67, 95% CI 0.64-0.70) in stratifying the MD and MD-phenocopy patients. The Revised MDC score was included as an alternative MDC, as in contrast to the Nijmegen MDC score the Revised MDC score does not consider tissue histopathology and tissue biochemistry findings (see Supplemental methods). D, Proportion of patients meeting criteria indicative of MD in our study population, stratified by underlying molecular diagnosis. E, Solved patients ordered by the rank of their respective disease-causing gene amongst all OMIM disease genes by HPO phenotype semantic similarity (SS). Patients above the horizontal lines mark those in whom the correct gene defect was predicted by HPO phenotype within the highest three and five SS scores, respectively. WES, whole exome sequencing; MDC,

mitochondrial disease criteria; AUC, area under the curve; BG, basal ganglia; BS, brain stem; RCC, respiratory chain complex; SS, semantic similarity.

Figure 4. MD gene overview and variant detection in this study. Depiction of the functional category of all defined MD genes indicating the number of disease genes per functional category with disease-causing variants detected in this study. All disease genes are listed beneath. "Pathogenic" or "likely pathogenic" variants were detected in genes highlighted in color in ≥ 5 cases and in those depicted in black in ≥ 1 case. "Pathogenic" or "likely pathogenic" variants were not detected in the genes depicted in grey in this study. In total 199 of the 416 defined MD genes were reported with defects. Genes marked with an asterisk were novel disease gene discoveries made within the cohort over the 10-year period of this study (**Table S2**).

References

https://doi.org/10.1002/ajmg.c.31874

Barca, E., Long, Y., Cooley, V., Schoenaker, R., Emmanuele, V., Dimauro, S., Cohen, B. H., Karaa, A., Vladutiu, G. D., Haas, R., Van Hove, J. L. K., Scaglia, F., Parikh, S., Bedoyan, J. K., Debrosse, S. D., Gavrilova, R. H., Saneto, R. P., Enns, G. M., Stacpoole, P. W., ... Hirano, M. (2020). Mitochondrial diseases in North America: An of the **NAMDC** Registry. Neurology: Genetics, analysis 6(2). https://doi.org/10.1212/NXG.00000000000000402 Bick, D., Bick, S. L., Dimmock, D. P., Fowler, T. A., Caulfield, M. J., & Scott, R. H. (2021). An online compendium of treatable genetic disorders. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 187(1), 48-54.

Bonora, E., Chakrabarty, S., Kellaris, G., Tsutsumi, M., Bianco, F., Bergamini, C., ... & De Giorgio, R. (2021). Biallelic variants in LIG3 cause a novel mitochondrial neurogastrointestinal encephalomyopathy. Brain.

Distelmaier, F., Huppke, P., Pieperhoff, P., Amunts, K., Schaper, J., Morava, E., ... & Karenfort, M. (2013). Biotin-responsive basal ganglia disease: a treatable differential diagnosis of leigh syndrome. In JIMD Reports-Case and Research Reports, Volume 13 (pp. 53-57). Springer, Berlin, Heidelberg.

Distelmaier, F., Haack, T. B., Wortmann, S. B., Mayr, J. A., & Prokisch, H. (2017). Treatable mitochondrial diseases: cofactor metabolism and beyond. Brain, 140(2), e11-e11.

Firth, H. V., Richards, S. M., Bevan, A. P., Clayton, S., Corpas, M., Rajan, D., ... & Carter, N. P. (2009). DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources. The American Journal of Human Genetics, 84(4), 524-533.

French, C. E., Delon, I., Dolling, H., Sanchis-Juan, A., Shamardina, O., Mégy, K., ... & Raymond, F. L. (2019). Whole genome sequencing reveals that genetic conditions are frequent in intensively ill children. Intensive care medicine, 45(5), 627-636.

Ganetzky, R. D., Stendel, C., McCormick, E. M., Zolkipli-Cunningham, Z., Goldstein, A. C., Klopstock, T., & Falk, M. J. (2019). MT-ATP6 mitochondrial disease variants: Phenotypic and biochemical features analysis in 218 published cases and cohort of 14 new cases. Human Mutation, 40(5), 499–515. https://doi.org/10.1002/humu.23723

Gorman, G. S., Chinnery, P. F., DiMauro, S., Hirano, M., Koga, Y., McFarland, R., Suomalainen, A., Thorburn, D. R., Zeviani, M., & Turnbull, D. M. (2016). Mitochondrial diseases. Nature Reviews Disease Primers, 2. https://doi.org/10.1038/nrdp.2016.80

Gorman, G. S., Schaefer, A. M., Ng, Y., Gomez, N., Blakely, E. L., Alston, C. L., Feeney, C., Horvath, R., Yu-Wai-Man, P., Chinnery, P. F., Taylor, R. W., Turnbull, D. M., & McFarland, R. (2015). Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Annals of Neurology, 77(5), 753–759. https://doi.org/10.1002/ana.24362

Greene, D., Richardson, S., & Turro, E. (2017). OntologyX: A suite of R packages for working with ontological data. Bioinformatics, 33(7), 1104–1106. https://doi.org/10.1093/bioinformatics/btw763

Guillen Sacoto, M. J., Tchasovnikarova, I. A., Torti, E., Forster, C., Andrew, E. H., Anselm, I., Baranano, K. W., Briere, L. C., Cohen, J. S., Craigen, W. J., Cytrynbaum, C., Ekhilevitch, N., Elrick, M. J., Fatemi, A., Fraser, J. L., Gallagher, R. C., Guerin, A., Haynes, D., High, F. A., ... Juusola, J. (2020). De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial Dysmorphism. American Journal of Human Genetics, 107(2), 352–363. https://doi.org/10.1016/j.ajhg.2020.06.013

Haack, T. B., Makowski, C., Yao, Y., Graf, E., Hempel, M., Wieland, T., ... & Prokisch, H. (2012). Impaired riboflavin transport due to missense mutations in SLC52A2 causes Brown-Vialetto-Van Laere syndrome. Journal of inherited metabolic disease, 35(6), 943-948.

Haack, T. B., Jackson, C. B., Murayama, K., Kremer, L. S., Schaller, A., Kotzaeridou, U., de Vries, M. C., Schottmann, G., Santra, S., Büchner, B., Wieland, T., Graf, E., Freisinger, P., Eggimann, S., Ohtake, A., Okazaki, Y., Kohda, M., Kishita, Y., Tokuzawa, Y., ... Klopstock, T. (2015). Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement. Annals of Clinical and Translational Neurology, 2(5), 492–509. https://doi.org/10.1002/acn3.189

Hoytema van Konijnenburg, E. M. M., Wortmann, S. B., Koelewijn, M. J., Tseng, L. A., Houben, R., Stöckler-Ipsiroglu, S., Ferreira, C. R., & van Karnebeek, C. D. M. (2021). Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app. Orphanet Journal of Rare Diseases, 16(1), 170. https://doi.org/10.1186/s13023-021-01727-2

Kohda, M., Tokuzawa, Y., Kishita, Y., Nyuzuki, H., Moriyama, Y., Mizuno, Y., Hirata, T., Yatsuka, Y., Yamashita-Sugahara, Y., Nakachi, Y., Kato, H., Okuda, A., Tamaru, S., Borna, N. N., Banshoya, K., Aigaki, T., Sato-Miyata, Y., Ohnuma, K., Suzuki, T., ... Okazaki, Y. (2016). A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies. PLOS Genetics, 12(1), e1005679. https://doi.org/10.1371/journal.pgen.1005679

Köhler, S., Gargano, M., Matentzoglu, N., Carmody, L. C., Lewis-Smith, D., Vasilevsky, N. A., Danis, D., Balagura, G., Baynam, G., Brower, A. M., Callahan, T. J., Chute, C. G., Est, J. L., Galer, P. D., Ganesan, S., Griese, M., Haimel, M., Pazmandi, J., Hanauer, M., ... Robinson, P. N. (2021). The human phenotype ontology in 2021. Nucleic Acids Research, 49(D1), D1207–D1217. https://doi.org/10.1093/nar/gkaa1043 Kopajtich, R., Smirnov, D., Stenton, S. L., Loipfinger, S., Meng, C., Scheller, I. F., Freisinger, P., Baski, R., Berutti, R., Behr, J., Bucher, M., Distelmaier, F., Gusic, M., Hempel, M., Kulterer, L., Mayr, J., Meitinger, T., Mertes, C., Metodiev, M. D., ... Prokisch, H. (2021). Integration of proteomics with genomics and transcriptomics increases the diagnostic rate of Mendelian disorders. MedRxiv.

Kremer, L. S., Bader, D. M., Mertes, C., Kopajtich, R., Pichler, G., Iuso, A., ... & Prokisch, H. (2017). Genetic diagnosis of Mendelian disorders via RNA sequencing. Nature communications, 8(1), 1-11.

Legati, A., Reyes, A., Nasca, A., Invernizzi, F., Lamantea, E., Tiranti, V., Garavaglia, B., Lamperti, C., Ardissone, A., Moroni, I., Robinson, A., Ghezzi, D., & Zeviani, M. (2016). New genes and pathomechanisms in mitochondrial disorders unraveled by NGS technologies. Biochimica et Biophysica Acta - Bioenergetics, 1857(8), 1326–1335. https://doi.org/10.1016/j.bbabio.2016.02.022

Lissens, W., De Meirleir, L., Seneca, S., Liebaers, I., Brown, G. K., Brown, R. M., Ito, M., Naito, E., Kuroda, Y., Kerr, D. S., Wexler, I. D., Patel, M. S., Robinson, B. H., Seyda, A., & Lissens, : W. (2000). Mutations in the X-Linked Pyruvate Dehydrogenase (E1) α Subunit Gene (PDHA1) in Patients With a Pyruvate Dehydrogenase Complex Deficiency. HUMAN MUTATION, 15, 209–219. https://doi.org/10.1002/(SICI)1098-1004(200003)15:3

Marti-Sanchez, L., Baide-Mairena, H., Marcé-Grau, A., Pons, R., Skouma, A., López-Laso, E., Sigatullina, M., Rizzo, C., Semeraro, M., Martinelli, D., Carrozzo, R., Dionisi-Vici, C., González-Gutiérrez-Solana, L., Correa-Vela, M., Ortigoza-Escobar, J. D., Sánchez-Montañez, Á., Vazquez, É., Delgado, I., Aguilera-Albesa, S., ... Pérez-Dueñas, B. (2020). Delineating the neurological phenotype in children with defects in the ECHS1 or HIBCH gene. Journal of Inherited Metabolic Disease, 44(2). https://doi.org/10.1002/jimd.12288

Morava, E., Van Den Heuvel, L., Hol, F., De Vries, M. C., Hogeveen, M., Rodenburg, R. J., & Smeitink, J. A. M. (2006). Mitochondrial disease criteria: Diagnostic applications in children. Neurology, 67(10), 1823–1826. https://doi.org/10.1212/01.wnl.0000244435.27645.54

Ng, Y. S., Martikainen, M. H., Gorman, G. S., Blain, A., Bugiardini, E., Bunting, A., Schaefer, A. M., Alston, C. L., Blakely, E. L., Sharma, S., Hughes, I., Lim, A., de Goede, C., McEntagart, M., Spinty, S., Horrocks, I., Roberts, M., Woodward, C. E.,

Chinnery, P. F., ... McFarland, R. (2019). Pathogenic variants in MT-ATP6: A United Kingdom–based mitochondrial disease cohort study. Annals of Neurology, 86(2), 310–315. https://doi.org/10.1002/ana.25525

Ogawa, E., Shimura, M., Fushimi, T., Tajika, M., Ichimoto, K., Matsunaga, A., Tsuruoka, T., Ishige, M., Fuchigami, T., Yamazaki, T., Mori, M., Kohda, M., Kishita, Y., Okazaki, Y., Takahashi, S., Ohtake, A., & Murayama, K. (2017). Clinical validity of biochemical and molecular analysis in diagnosing Leigh syndrome: a study of 106 Japanese patients. Journal of Inherited Metabolic Disease, 40(5), 685–693. https://doi.org/10.1007/s10545-017-0042-6

Ohtake, A., Murayama, K., Mori, M., Harashima, H., Yamazaki, T., Tamaru, S., Yamashita, Y., Kishita, Y., Nakachi, Y., Kohda, M., Tokuzawa, Y., Mizuno, Y., Moriyama, Y., Kato, H., & Okazaki, Y. (2014). Diagnosis and molecular basis of mitochondrial respiratory chain disorders: Exome sequencing for disease gene identification. Biochimica et Biophysica Acta - General Subjects, 1840(4), 1355–1359. https://doi.org/10.1016/j.bbagen.2014.01.025

Pronicka, E., Piekutowska-Abramczuk, D., Ciara, E., Trubicka, J., Rokicki, D., Karkucinska-Wieckowska, A., Pajdowska, M., Jurkiewicz, E., Halat, P., Kosinska, J., Pollak, A., Rydzanicz, M., Stawinski, P., Pronicki, M., Krajewska-Walasek, M., & Płoski, R. (2016). New perspective in diagnostics of mitochondrial disorders: Two years' experience with whole-exome sequencing at a national paediatric centre. Journal of Translational Medicine, 14(1), 174. https://doi.org/10.1186/s12967-016-0930-9

Puusepp, S., Reinson, K., Pajusalu, S., Murumets, Ü., Õiglane-Shlik, E., Rein, R., Talvik, I., Rodenburg, R. J., & Õunap, K. (2018). Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in

Estonia. Molecular Genetics and Metabolism Reports, 15, 80–89. https://doi.org/10.1016/j.ymgmr.2018.03.004

Rahman, S., & Copeland, W. C. (2019). POLG-related disorders and their neurological manifestations. Nature Reviews Neurology, 15(1), 40–52. https://doi.org/10.1038/s41582-018-0101-0

Repp, B. M., Mastantuono, E., Alston, C. L., Schiff, M., Haack, T. B., Rötig, A., Ardissone, A., Lombès, A., Catarino, C. B., Diodato, D., Schottmann, G., Poulton, J., Burlina, A., Jonckheere, A., Munnich, A., Rolinski, B., Ghezzi, D., Rokicki, D., Wellesley, D., ... Wortmann, S. (2018). Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? Orphanet Journal of Rare Diseases, 13(1), 120. https://doi.org/10.1186/s13023-018-0784-8 Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., & Rehm, H. L. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–424. https://doi.org/10.1038/gim.2015.30

Riley, L. G., Cowley, M. J., Gayevskiy, V., Minoche, A. E., Puttick, C., Thorburn, D. R., Rius, R., Compton, A. G., Menezes, M. J., Bhattacharya, K., Coman, D., Ellaway, C., Alexander, I. E., Adams, L., Kava, M., Robinson, J., Sue, C. M., Balasubramaniam, S., & Christodoulou, J. (2020). The diagnostic utility of genome sequencing in a pediatric cohort with suspected mitochondrial disease. Genetics in Medicine, 22(7), 1254–1261. https://doi.org/10.1038/s41436-020-0793-6

Russell, O. M., Gorman, G. S., Lightowlers, R. N., & Turnbull, D. M. (2020). Mitochondrial diseases: hope for the future. Cell, 181(1), 168-188.

Schlieben, L. D., & Prokisch, H. (2020). The Dimensions of Primary Mitochondrial Disorders. Frontiers in Cell and Developmental Biology, 8. https://doi.org/10.3389/fcell.2020.600079

Stendel, C., Neuhofer, C., Floride, E., Yuqing, S., Ganetzky, R. D., Park, J., Freisinger, P., Kornblum, C., Kleinle, S., Schöls, L., Distelmaier, F., Stettner, G. M., Büchner, B., Falk, M. J., Mayr, J. A., Synofzik, M., Abicht, A., Haack, T. B., Prokisch, H., ... Klopstock, T. (2020). Delineating MT-ATP6 -associated disease: From isolated neuropathy to early onset neurodegeneration. Neurology: Genetics, 6(1), 393. https://doi.org/10.1212/NXG.000000000000000393

Stenton, S. L., & Prokisch, H. (2020). Genetics of mitochondrial diseases: Identifying mutations to help diagnosis. EBioMedicine, 56, 102784. https://doi.org/10.1016/j.ebiom.2020.102784

Stenton, S. L., Sheremet, N. L., Catarino, C. B., Andreeva, N., Assouline, Z., Barboni, P., Barel, O., Berutti, R., Bychkov, I. O., Caporali, L., Capristo, M., Carbonelli, M., Cascavilla, M. L., Charbel Issa, P., Freisinger, P., Gerber, S., Ghezzi, D., Graf, E., Heidler, J., ... Prokisch, H. (2021). Impaired complex I repair causes recessive Leber's hereditary optic neuropathy. Journal of Clinical Investigation. https://doi.org/10.1172/jci138267

Tan, J., Wagner, M., Stenton, S. L., Strom, T. M., Wortmann, S. B., Prokisch, H., Meitinger, T., Oexle, K., & Klopstock, T. (2020). Lifetime risk of autosomal recessive mitochondrial disorders calculated from genetic databases. EBioMedicine, 54. https://doi.org/10.1016/j.ebiom.2020.102730

Taylor, R. W., Pyle, A., Griffin, H., Blakely, E. L., Duff, J., He, L., Smertenko, T.,Alston, C. L., Neeve, V. C., Best, A., Yarham, J. W., Kirschner, J., Schara, U., Talim,B., Topaloglu, H., Baric, I., Holinski-Feder, E., Abicht, A., Czermin, B., ... Chinnery,

P. F. (2014). Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. JAMA - Journal of the American Medical Association, 312(1), 68–77. https://doi.org/10.1001/jama.2014.7184

Tetreault, M., Fahiminiya, S., Antonicka, H., Mitchell, G. A., Geraghty, M. T., Lines, M., Boycott, K. M., Shoubridge, E. A., Mitchell, J. J., Michaud, J. L., & Majewski, J. (2015). Whole-exome sequencing identifies novel ECHS1 mutations in Leigh syndrome. Human Genetics, 134(9), 981–991. https://doi.org/10.1007/s00439-015-1577-y

Theunissen, T. E. J., Nguyen, M., Kamps, R., Hendrickx, A. T., Sallevelt, S. C. E. H., Gottschalk, R. W. H., Calis, C. M., Stassen, A. P. M., De Koning, B., Mulder-Den Hartog, E. N. M., Schoonderwoerd, K., Fuchs, S. A., Hilhorst-Hofstee, Y., De Visser, M., Vanoevelen, J., Szklarczyk, R., Gerards, M., De Coo, I. F. M., Hellebrekers, D. M. E. I., & Smeets, H. J. M. (2018). Whole exome sequencing is the preferred strategy to identify the genetic defect in patients with a probable or possible mitochondrial cause. Frontiers in Genetics, 9(OCT), 400. https://doi.org/10.3389/fgene.2018.00400
Witters, P., Saada, A., Honzik, T., Tesarova, M., Kleinle, S., Horvath, R., Goldstein, A., & Morava, E. (2018). Revisiting mitochondrial diagnostic criteria in the new era of

Wortmann, S. B., Koolen, D. A., Smeitink, J. A., van den Heuvel, L., & Rodenburg, R. J. (2015). Whole exome sequencing of suspected mitochondrial patients in clinical practice. Journal of Inherited Metabolic Disease, 38(3), 437–443. https://doi.org/10.1007/s10545-015-9823-y

in

Medicine,

genomics.

Genetics

https://doi.org/10.1038/gim.2017.125

444-451.

20(4),

Wortmann, S. B., Mayr, J. A., Nuoffer, J. M., Prokisch, H., & Sperl, W. (2017). A Guideline for the Diagnosis of Pediatric Mitochondrial Disease: The Value of Muscle

and Skin Biopsies in the Genetics Era. Neuropediatrics, 48(4), 309–314. https://doi.org/10.1055/s-0037-1603776

Yépez, V. A., Gusic, M., Kopajtich, R., Mertes, C., Smith, N. H., Alston, C. L., Berutti, R., Blessing, H., Ciara, E., Procopio, E., Ribes, A., Rötig, A., Schwarzmayr, T., Staufner, C., Stenton, S. L., Strom, T. M., Taylor, R. W., Terrile, C., Tort, F., ... Prokisch, H. (2021). Clinical implementation of RNA sequencing for Mendelian disease diagnostics. Dorota Piekutowska-Abramczuk, 10, 2021.04.01.21254633. https://doi.org/10.1101/2021.04.01.21254633

Zhou, J., Li, J., Stenton, S. L., Ren, X., Gong, S., Fang, F., & Prokisch, H. (2020). NAD (P) HX dehydratase (NAXD) deficiency: a novel neurodegenerative disorder exacerbated by febrile illnesses. Brain, 143(2), e8-e8.


Zhou, L., Deng, J., Stenton, S. L., Zhou, J., Li, H., Chen, C., ... & Fang, F. (2020). Case Report: Rapid Treatment of Uridine-Responsive Epileptic Encephalopathy Caused by CAD Deficiency. Frontiers in Pharmacology, 11, 1956.


Table 1. Key demographic, genetic, clinical, and biochemical features stratified by molecular diagnosis.


		Total	MD	MD-phenocopy	Unsolved
Patients		2,023	801/2,023 (40%)	308/2,023 (15%)	914/2,023 (45%)
Gender	Male	1,066/2,023 (53%)			
Onset	Neonatal (≤28 days)	545/2,023 (27%)			
	Infantile (>28 days, <2 years)	709/2,023 (35%)			
	Early childhood (≥2 years, <5 years)	444/2,023 (22%)			
	Childhood (≥5 years, <12 years)	217/2,023 (11%)			
	Juvenile (≥12 years, <18 years)	107/2,023 (5%)			
Diagnostic rate	Study population	1,109/2,023 (55%), 94/1,109, 8% de novo	801/2,023 (40%), 33/801, 4% <i>de novo</i>	308/2,023 (15%), 61/308, 20% de novo	
	Singleton WES, <i>de novo</i>	986/1,779 (55%), 60/986, 6% de novo			
	Trio WES, de novo	123/244 (50%), 34/123, 28% de novo			
Median HPO phenotypes (range)		8 (2-40)	8 (2-40)	7 (2-31)	8 (2-35)


Median systems involved (range)		4 (1-12)	4 (1-12)	4 (1-11)	4 (1-11)
Abnormal RCC activity		889 (44%)	399 (50%)	104 (34%)	386 (42%)
Elevated lactate (serum and/or CSF)		1,024 (51%)	509 (64%)	97 (31%)	418 (46%)
MRI abnormality (BG and/or BS)		524 (26%)	270 (34%)	45 (15%)	209 (23%)
MDC score	Nijmegen MDC score	6.0 ± 2.3	6.7 ± 2.4	5.2 ± 2.2	5.8 ± 2.2
	Revised MDC score	4.9 ± 2.0	5.4 ± 2.1	4.5 ± 1.8	4.7 ± 2.0

WES, whole exome sequencing; HPO, human phenotype ontology; RCC, respiratory chain complex; CSF, cerebral spinal fluid; MRI, magnetic resonance imaging; BG, basal ganglia; BS, brain stem; MDC, mitochondrial disease criteria.









		OXPHOS machinery				Mitochondrial DN	A maintenance, exp	ression, and translat	tion
CI subunits MT-ND1	CI assembly factors	CIII subunits	CIV assembly factors	CV assembly factors	Replication, maintenance,	RNA processing	Mitochondrial ribosomes	Mitochondrial tRNAs	I Mitochondrial tRNA
MT-ND2	ACAD9*	MT-CYB	CEP89	ATPAF2	and	ELAC2*	MRPL3*	MT-TA	synthetases
MT-ND3	ECSIT	UQCRB	COA3	ATP5MD	transcription	ERAL1	MRPL12	MT-TC	AARS2*
MT-ND4	FOXRED1	UQCRC2	COA5	OXA1L	APTX	GTPBP3*	MRPL24	MT-TD	CARS2
MT-ND4L	NDUFAF1	UQCRFS1*	COA6	TMEM70	DNA2	HSD17B10	MRPL38*	MT-TE	DARS2
MT-ND5	NDUFAF2	UQCRQ	COA7		FBXL4*	LRPPRC	MRPL44*	MT-TF	EARS2*
MT-ND6	NDUFAF3		COX10	Coenzyme	LIG3*	MRM2	MRPS2	MT-TG	FARS2
NDUFA1	NDUFAF4	CIII assembly	COX14	Q10	MGME1*	MTO1*	MRPS7	MT-TH	GARS
NDUFA2	NDUFAF5	factors	COX15	COQ2	MPV17	MTPAP	MRPS14	MT-TI	GATB
NDUFA6	NDUFAF6	BCS1L	COX20	COQ4*	POLG	NSUN3	MRPS16	MT-TK	GATC
NDUFA8	NDUFAF7	LYRM7	FASTKD2	COQ5	POLG2	PDE12	MRPS22	MT-TL1	HARS2
NDUFA9	NDUFAF8*	TTC19	OXA1L	COQ6	POLRMT	PNPT1*	MRPS23	MT-TL2	IARS2
NDUFA10	NUBPL	UQCC2*	PET100	COQ7	RNASEH1	PUS1	MRPS25	MT-TM	KARS
NDUFA11	TIMMDC1*	UQCC3	PET117	COQ8A	SLC25A4	THG1L	MRPS28*	MT-TN	LARS2
NDUFA12*	TMEM126A		SC01	COQ8B	SSBP1	TRIT1	MRPS34*	MT-TP	MARS2
NDUFA13	TMEM126B*	CIV subunits	SCO2	COQ9	TFAM	TRMT5*	MT-RNR1	MT-TQ	MTFMT
NDUFB3*		COX4I1	SURF1	PDSS1	TMEM65	TRMT10C*	MT-RNR2	MT-TR	NARS2
NDUFB8*	CI	COX4I2	TACO1	PDSS2	TOP3A	TRMU	PTCD3	MT-TS1	PARS2
NDUFB9	maintenance	COX5A			TWNK	TRNT1		MT-TS2	QRSL1
NDUFB10	DNAJC30*	COX6A1	CV subunits	Cytochrome	XRCC4			MT-TT	RARS2
NDUFB11		COX6A2	ATP5F1A	С		Translation		MT-TV	SARS2
NDUFS1	CII subunits	COX6B1	ATP5F1D	CYCS	Nucleotide	regulation		MT-TW	TARS2*
NDUFS2	SDHA	COX7B	ATP5F1E	HCCS	pool	C12orf65		MT-TY	VARS2*
NDUFS3	SDHB	COX8A	MT-ATP6		maintenance	C1QBP*	_		WARS2*
NDUFS4	SDHC	MT-CO1	MT-ATP8		ABAT	GFM1			YARS2
NDUFS6	SDHD	MT-CO2			DGUOK	GFM2			
					RRM2B	GUF1			
NDUFS7		MT-CO3			0.4.141110.4	DIANDA			
NDUFS8	CII assembly	NDUFA4			SAMHD1	RMND1			
NDUFS8 NDUFV1	CII assembly factors	NDUFA4	Metabolism (of substrates	SUCLA2 SUCLG1	RMND1 TSFM TUFM		Metabolism of toxic	Other and unknown
NDUFS8 NDUFV1 Mitochondrial dy	factors onlined rnamics, homeostasis, Mitochondrial	NDUFA4 and quality control Mitochondrial	Fatty acid	Redox	SUCLA2 SUCLG1 Me	TSFM	NADPH	Metabolism of toxic compounds D2HGDH	Other and unknown
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2	rnamics, homeostasis, Mitochondrial protein quality	and quality control Mitochondrial membrane	Fatty acid oxidation	Redox carriers	SUCLA2 SUCLG1	TSFM TI JFM etabolism of cofactors Copper transport	metabolism	compounds D2HGDH ECHS1*	
NDUFS8 NDUFV1 Mitochondrial dy	rnamics, homeostasis, Mitochondrial protein quality control	NDUFA4 and quality control Mitochondrial membrane phospholipid	Fatty acid oxidation ACADS	Redox carriers GOT2	SUCLA2 SUCLG1 Mo Iron-sulphur cluster protein biosynthesis	TSFM TUFM etabolism of cofactors Copper transport CCS	metabolism HAAO	compounds D2HGDH ECHS1* ETHE1	ABAT ANO10 CISD2
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2	rnamics, homeostasis, Mitochondrial protein quality	NDUFA4 and quality control Mitochondrial membrane phospholipid and import	Fatty acid oxidation ACADS ACADVL	Redox carriers GOT2 MDH1	SUCLA2 SUCLA1 Me Iron-sulphur cluster protein biosynthesis BOLA3*	TSFM THEM ctabolism of cofactors Copper transport CCS COA6	metabolism HAAO KYNU	COMPOUNDS D2HGDH ECHS1* ETHE1 HIBCH	ABAT ANO10 CISD2 CTBP1
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3	namics, homeostasis, Mitochondrial protein quality control AFG3L2	NDUFA4 and quality control Mitochondrial membrane phospholipid	Fatty acid oxidation ACADS	Redox carriers GOT2	SUCLA2 SLICE G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L	TSFM THEM tabolism of cofactors Copper transport CCS COA6 SCO1	metabolism HAAO KYNU NADK2	COMPOUNDS D2HGDH ECHS1* ETHE1 HIBCH HTT	ABAT ANO10 CISD2 CTBP1 C19of12
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1	mamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1	Fatty acid oxidation ACADS ACADVL CPT2	Redox carriers GOT2 MDH1	SUCLA2 SUCLA1 Me Iron-sulphur cluster protein biosynthesis BOLA3*	TSFM THEM ctabolism of cofactors Copper transport CCS COA6	metabolism HAAO KYNU NADK2 NAXD*	Compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF*	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism	SUCLA2 SUICE G1 Mo Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR	TSFM THEM tabolism of cofactors Copper transport CCS COA6 SCO1	metabolism HAAO KYNU NADK2	COMPOUNDS D2HGDH ECHS1* ETHE1 HIBCH HTT	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFP* STAT2	mamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT	SUCLA2 SHICH G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57	TSFM THEM ctabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism	metabolism HAAO KYNU NADK2 NAXD* NAXE*	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF*	mamics, homeostasis, Mitochondrial protein quality control AFG31_2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD	SUCLA2 SLICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1	TSFM TUFM copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMNAT1 NNT	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C190rf12 DCC DIAPH1 EMC1
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB CLPP CLPX HSPA9 HSPD1 HSPE1	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC	SUCLA2 SITICI G1 Mo Iron-sulphur cluster protein blosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2	TSFM THEM THEM tabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1*	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMNAT1 NNT Selenocysteine	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFP* STAT2	mamics, homeostasis, Mitochondrial protein quality control AFG31_2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1	SUCLA2 SITICI G1 Mo Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU	TSFM TITEM etabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMMAT1 NNT Selenocysteine metabolism	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIFSA
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB	SUCLA2 SLICI G1 Mo Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4	TSFM TUFM TUFM copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMNAT1 NNT Selenocysteine metabolism SECISBP2	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFP* STAT2 SLC25A46 Stability OPA1 MICOS	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1	SUCLA2 SITICI G1 Mo Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU	TSFM TITEM etabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMMAT1 NNT Selenocysteine metabolism	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19suf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX	SUCLA2 SITICI G1 Mo Iron-sulphur cluster protein blosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1	TSFM TLIFM tabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMNAT1 NNT Selenocysteine metabolism SECISBP2	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIFSA MPV17 PLA2G6 PNPLA4
NDUFS8 NDUFV1 Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD2	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDHX	SUCLA2 SITICI G1 Me Iron-sulphur cluster protein blosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL	TSFM THEM Part of the state of	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMNAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19suf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD2 CHCHD10	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDHX PDK3 PDPR PDP1	SUCLA2 SLICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFS1 NFS1 NUBPL Copper	TSFM TIJEM relation of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A2 Thiamine metabolism	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMMAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1
NDUFS8 NDUFV1 Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD2 CHCHD10 MICOS13	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIIMM8A TIIMM22	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial	SUCLA2 SLICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport	TSFM TUFM tabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A3 Thiamine metabolism and transport	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMNAT1 NNT Selenocysteine metabolism secisBP2 SEPSECS Haem biosynthesis ALAS2 ABCB6	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTN4IP1 SLC39A8
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD2 CHCHD10	factors mamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers	SUCLA2 SILICI G1 Me Iron-sulphur cluster protein blosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NEU1 NUBPL Copper transport CCS	TSFM THEM Part of the second	metabolism HAAO KYNU NADK2 NAXD* NAXC* NAXC* NMNAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABC86 ABC87	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART
NDUFS8 NDUFV1 Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD2 CHCHD10 MICOS13	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDHX PDPR PDPR PDP1 Mitochondrial carriers MPC1	SUCLA2 SLICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6	TSFM TIJFM TIJFM copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A2 Thamine metabolism and transport sLC19A2 SLC19A3	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMMAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABCB6 ABCB7 COX10	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5
NDUFS8 NDUFV1 Fusion MFN2 NME3 Fission DNM1L GDAP1 MFP* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD2 CHCHD10 MICOS13 SLC25A46 Morphology MIEF2	factors mamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers	SUCLA2 SLICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6 SCO1	TSFM TLIFM retabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A3 Thiamine metabolism and transport SLC19A2 SLC19A2 SLC19A3 SLC25A19	metabolism HAAO KYNU NADK2 NAXD* NAXC* NMNAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABCB6 ABCB7 COX10 COX15	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTN4IP1 SLC39A8 SPART SPATA5 STXBP1
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD10 MICOS13 SLC25A46 Morphology MIEFS MISTO1	mamics, homeostasis, Mitochondrial protein quality control AFG31_2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect APOPT1*	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70 XPNPEP3 Ca2+	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2 OXCT1 Tricarboxylic acid cycle	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers MPC1 SLC25A3 SLC25A10* SLC25A12	SUCLA2 SLICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6	TSFM TIJFM TIJFM copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A2 Thamine metabolism and transport sLC19A2 SLC19A3	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMMAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABCB6 ABCB7 COX10	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C199df12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5 STXBP1 TANGO2*
NDUFS8 NDUFV1 Fusion MFN2 NME3 Fission DNM1L GDAP1 MFP* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD2 CHCHD10 MICOS13 SLC25A46 Morphology MIEF2	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect APOPT1* DIABLO	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70 XPNPEP3 Ca2+ homoeostasis	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFBH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2 OXCT1 Tricarboxylic acid cycle enzymes	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers MPC1 SLC25A3 SLC25A10* SLC25A12 SLC25A26	SUCLA2 SLICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6 SCO1 SCO2 COA	TSFM TLIFM retabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A3 Thiamine metabolism and transport SLC19A2 SLC19A2 SLC19A3 SLC25A19	metabolism HAAO KYNU NADK2 NAXD* NAXC* NAXC* NMNAT1 NNT Selenocysteine metabolism SECISSP2 SEPSECS Haem biosynthesis ALAS2 ABC86 ABC87 COX10 COX15 CYCS	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIFSA MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5 STXBP1 TANGO2* TIMEM65
NDUFS8 NDUFV1 Fusion MFN2 NME3 Fission DNM1. GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD10 MICOS13 SLC25A46 Morphology MIEFS MISTO1	mamics, homeostasis, Mitochondrial protein quality control AFG31_2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect APOPT1*	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70 XPNPEP3 Ca2+ homoeostasis CYP24A1	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCSL HMGCS2 OXCT1 Tricarboxylic acid cycle enzymes ACC2*	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers MPC1 SLC25A3 SLC25A10* SLC25A12 SLC25A16	SUCLA2 SILICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NEU1 NUBPL Copper transport CCS COA6 SCO1 SCO2 COA metabolism	TSFM THEM retabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A3 Thiamine metabolism and transport SLC19A2 SLC19A3 SLC25A19 TPK1*	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMMAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABC86 ABC87 COX10 COX15 CYCS HCCS PPOX SFXN4*	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C199df12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5 STXBP1 TANGO2*
NDUFS8 NDUFV1 Fusion MFN2 NME3 Fission DNM1. GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD10 MICOS13 SLC25A46 Morphology MIEFS MISTO1	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect APOPT1* DIABLO	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70 XPNPEP3 Ca2+ homoeostasis CYP24A1 MICOS13	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2 OXCT1 Tricarboxylic acid cycle enzymes ACO2* ALDH18A1	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDHS PDPR PDPR Mitochondrial carriers MPC1 SLC25A13 SLC25A10 SLC25A12 SLC25A12 SLC25A11 SLC25A15	SUCLA2 SUICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6 SCO1 SCO2 COA metabolism and transport	TSFM TUFM TUFM contained by tabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A3 Thiamine metabolism and transport SLC19A2 SLC19A3 SLC25A19 TPK1* Lipoic acid biosynthesis DLD	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMNAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABC86 ABC87 COX10 COX15 CYCS HCCS PPOX	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C19orf12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5 STXBP1 TANGO2* TMEM65 TRAK1
NDUFS8 NDUFV1 Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD10 MICOS13 SLC25A46 Morphology MIEFS MISTO1	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect APOPT1* DIABLO	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70 XPNPEP3 Ca2+ homoeostasis CYP24A1 MICOS13 MICU1	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2 OXCT1 Tricarboxylic acid cycle enzymes ACO2* ALDH18A1 DLST	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers MPC1 SLC25A3 SLC25A10 SLC25A12 SLC25A12 SLC25A15 SLC25A15 SLC25A15	SUCLA2 SILICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6 SCO1 SCO2 CoA metabolism and transport COASY	TSFM TIJFM TIJFM retabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC25A32 SLC52A1 SLC52A2 SLC52A3 Thiamine metabolism and transport SLC19A2 SLC19A2 SLC19A2 SLC19A3 SLC25A19 TPK1* Lipoic acid biosynthesis DLD LIAS	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMNAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABC86 ABC87 COX10 COX15 CYCS HCCS PPOX SFXN4* SLC25A38	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C199d12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5 STXBP1 TANGO2* TMEM65 TRAK1 VPS13C
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD10 MICOS13 SLC25A46 Morphology MIEFS MISTO1	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect APOPT1* DIABLO	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70 XPNPEP3 Ca2+ homoeostasis CYP24A1 MICOS13	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2 OXCT1 Tricarboxylic acid cycle enzymes ACC2² ALDH18A1 DLST FH	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers MPC1 SLC25A3 SLC25A10 SLC25A10 SLC25A15 SLC25A15 SLC25A26 SLC25A11 SLC25A21 SLC25A21 SLC25A22	SUCLA2 SLICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6 SCO1 SCO2 COA metabolism and transport COASY PANK2	TSFM TIJEM TIJEM copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A2 Thiamine metabolism and transport SLC19A2 SLC19A3 SLC25A19 TPK1* Lipoic acid biosynthesis DLD LIAS LIAS LIPT1	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMMAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABCB6 ABCB6 ABCB7 COX10 COX15 CYCS HCCS PCX SFXN4* SLC25A38 Biotin	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C199d12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5 STXBP1 TANGO2* TMEM65 TRAK1 VPS13C
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD10 MICOS13 SLC25A46 Morphology MIEFS MISTO1	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect APOPT1* DIABLO	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70 XPNPEP3 Ca2+ homoeostasis CYP24A1 MICOS13 MICU1	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2 OXCT1 Tricarboxylic acid cycle enzymes ACO2* ALDH18A1 DLST	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers MPC1 SLC25A3 SLC25A10 SLC25A12 SLC25A12 SLC25A15 SLC25A15 SLC25A15	SUCLA2 SUICI G1 Mo Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6 SCO1 SCO2 CA metabolism and transport COASY PANK2 PPCS*	TSFM TUFM TUFM tabolism of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A3 Thiamine metabolism and transport SLC19A2 SLC19A3 SLC25A19 TPK1* Lipoic acid biosynthesis DLD LIAS LIPT1 LIPT2*	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMMAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABCB6 ABCB7 COX15 CYCS PCOX FXNA* SLC25A38 Biotin metabolism	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C199d12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5 STXBP1 TANGO2* TMEM65 TRAK1 VPS13C
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD10 MICOS13 SLC25A46 Morphology MIEFS MISTO1	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect APOPT1* DIABLO	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70 XPNPEP3 Ca2+ homoeostasis CYP24A1 MICOS13 MICU1	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2 OXCT1 Tricarboxylic acid cycle enzymes ACO2* ALDH18A1 DLST FH IDH3A	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers MPC1 SLC25A3 SLC25A10 SLC25A10 SLC25A15 SLC25A15 SLC25A26 SLC25A11 SLC25A21 SLC25A21 SLC25A22	SUCLA2 SLICI G1 Me Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6 SCO1 SCO2 COA metabolism and transport COASY PANK2	TSFM TIJEM TIJEM copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC52A1 SLC52A2 SLC52A2 Thiamine metabolism and transport SLC19A2 SLC19A3 SLC25A19 TPK1* Lipoic acid biosynthesis DLD LIAS LIAS LIPT1	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMNAT1 NNT Selenocysteine metabolism BTD HABO KYNU NAXD* NAXE* NMNAT1 NNT Selenocysteine metabolism HABO KECISBP2 SEPSECS Haem Biosynthesis ALAS2 ABC86 ABC87 COX10 COX15 CYCS HCCS PPOX SFXN4* SLC25A38	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C199d12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5 STXBP1 TANGO2* TMEM65 TRAK1 VPS13C
NDUFS8 NDUFV1 Mitochondrial dy Fusion MFN2 NME3 Fission DNM1L GDAP1 MFF* STAT2 SLC25A46 Stability OPA1 MICOS complex CHCHD10 MICOS13 SLC25A46 Morphology MIEFS MISTO1	rnamics, homeostasis, Mitochondrial protein quality control AFG3L2 ATAD3A CLPB* CLPP CLPX HSPA9 HSPD1 HSPE1 HTRA2 LONP1 MIPEP PINK1 PITRM1 PMPCB PRKN SACS SPG7 TRAP1 Apoptosis defect APOPT1* DIABLO	and quality control Mitochondrial membrane phospholipid and import machinery AGK* AIFM1 CHKB DNAJC19 GFER OPA3 PAM16 PISD PMPCA PNPLA8 SERAC1 TAZ TIMM8A TIMM22 TIMM50 TOMM70 XPNPEP3 Ca2+ homoeostasis CYP24A1 MICOS13 MICU1	Fatty acid oxidation ACADS ACADVL CPT2 CRAT ETFA ETFB ETFDH FA2H HADHA HADHB PYCR1 SLC22A5 SLC25A20 Ketone bodies ACAT1 HMGCL HMGCS2 OXCT1 Tricarboxylic acid cycle enzymes ACO2* ALDH18A1 DLST FH IDH3A IDH3B	Redox carriers GOT2 MDH1 SLC25A13 Pyruvate metabolism DLAT DLD PC PDHA1 PDHB PDHX PDK3 PDPR PDP1 Mitochondrial carriers MPC1 SLC25A3 SLC25A10* SLC25A10* SLC25A15 SLC25A15 SLC25A21 SLC25A24 SLC25A24	SUCLA2 SUICI G1 Mo Iron-sulphur cluster protein biosynthesis BOLA3* FDX1L FDXR FXN GLRX5 IBA57 ISCA1 ISCA2 ISCU LYRM4 NFS1 NFU1 NUBPL Copper transport CCS COA6 SCO1 SCO2 CA metabolism and transport COASY PANK2 PPCS*	TSFM TIJFM TIJFM relation of cofactors Copper transport CCS COA6 SCO1 SCO2 Riboflavin metabolism and transport FLAD1* SLC25A32 SLC25A32 SLC52A1 SLC52A2 SLC52A3 Thiamine metabolism and transport sLC19A2 SLC19A3 SLC19A3 SLC25A19 TPK1* Lipoic acid biosynthesis DLD LIAS LIPT1 LIPT2* MCAT	metabolism HAAO KYNU NADK2 NAXD* NAXE* NMMAT1 NNT Selenocysteine metabolism SECISBP2 SEPSECS Haem biosynthesis ALAS2 ABCB6 ABCB7 COX15 CYCS PCOX FXNA* SLC25A38 Biotin metabolism	compounds D2HGDH ECHS1* ETHE1 HIBCH HTT IDH2 L2HGDH SLC25A1 SQOR TXN2	ABAT ANO10 CISD2 CTBP1 C199d12 DCC DIAPH1 EMC1 EXOSC3 FBXL4 FGF12 KIF5A MPV17 PLA2G6 PNPLA4 POP1 ROBO3 RTM4IP1 SLC39A8 SPART SPATA5 STXBP1 TANGO2* TMEM65 TRAK1 VPS13C